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SUMMARY: The consumption of EVOO in Mediterranean countries has shown beneficial effects. A wide 
range of evidence indicates that the phenolic compounds present in EVOO are endowed with anti-inflammatory 
properties. In this work, we evaluated the effects of dietary EVOO and treatment with its phenolic extract (PE) 
in a model of RA, the collagen-induced arthritis (CIA) in mice. On day 0, DBA-1/J mice were immunized 
with bovine collagen type II (CII). On day 21, the mice received a booster injection. We have demonstrated 
that EVOO and its PE decreases joint edema, cell migration, cartilage degradation and bone erosion. Our data 
indicate that dietary EVOO and PE treatment inhibit JNK, p38 and signal transducer and STAT-3. In addition, 
both EVOO and PE decrease NF-κB translocation leading to the down-regulation of the arthritic process. These 
results support the interest of natural diet components in the development of therapeutic products for arthritic 
conditions.
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RESUMEN: El aceite de oliva extra virgen y su fracción polifenólica previenen la respuesta inflamatoria y el daño 
articular en un modelo de artritis experimental en murino. El consumo de Aceite de oliva virgen extra (AOVE) en 
los países mediterráneos ha demostrado tener efectos beneficiosos. Una amplia gama de pruebas indica que los 
compuestos fenólicos presentes en el AOVE tienen propiedades anti-inflamatorias. En este trabajo, se evaluaron 
los efectos de AOVE y el tratamiento en dieta de su fracción polifenólica (FP) en un modelo de la artritis reu-
matoide inducida por colágeno (CIA) en ratones. En el día 0, los ratones DBA-1/J se inmunizaron con colágeno 
bovino tipo II (CII). En el día 21, los ratones recibieron una inyección de refuerzo. Hemos demostrado que el 
AOVE y su FP disminuyen conjuntamente el edema, la migración celular, la degradación del cartílago y erosión 
ósea. Nuestros datos indican que la dieta con AOVE y el tratamiento con FP inhiben JNK, p38 y el transductor 
de señal y activador de la transcripción 3 (STAT-3). Además, tanto el AOVE como la FP disminuyen la translo-
cación NF-κB que conduce a la mejora del proceso artrítico. Estos resultados apoyan el interés de una dieta con 
componentes naturales y el desarrollo de productos terapéuticos para desordenes artríticos.
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1. INTRODUCTION
Rheumatoid arthritis (RA) is a chronic systemic 
inflammatory disease characterized by inflamma-
tion of the synovial membrane and progressive 
destruction of the articular cartilage and bone. 
(Salgado and Maneiro, 2014).
RA patients exhibit a chronic inflammatory con-
dition which usually affects symmetrically arthro-
dial and small joints of the hands and feet.
Global prevalence of RA has been estimated to 
be around 0.5-1.0% of adults in developed countries 
with a large variation across regions and approxi-
mately three times more common in the female gen-
der. The disease may begin at any age, but around 
80% of all patients initiate the disease between the 
ages of 35 and 50 (Rudan et al., 2015).
Although the specific triggers and exact mecha-
nisms of  tissue damage in RA are still unknown, 
an increase in inflammatory mediators as well as 
a deregulation of  the immune system with uncon-
trolled T cell activity play a remarkable role in its 
pathogenesis. Pharmacological treatment in AR 
including non-steroidal anti-inflammatory drugs 
(NSAIDs), glucocorticoids, disease-modifying 
antirheumatic drugs (DMARDs) and biological 
agents have improved the signs and symptoms of 
RA, but these drugs are only effective in a frac-
tion of  patients and have other limitations includ-
ing a high cost, the requirement for parenteral 
administration and drastic side effects. Therefore, 
new therapeutic strategies are under investigation 
including nutritional therapy. The beneficial effects 
of  the Mediterranean diet have been proven not 
only in cardiovascular diseases but also in diabetes, 
obesity, arthritis and cancer (Cárdeno et al., 2013). 
Evidence points out that the Mediterranean diet 
decreases both pain and disease activity leading 
to better outcomes, and a decrease in the doses of 
anti-inflammatory drugs which cause considerable 
side effects (Smedslund et al., 2010).
Olive oil is the most commonly used culinary fat 
in the Mediterranean area and is described as a key 
bio-active food (Puertollano et al., 2010). Extra vir-
gin olive oil (EVOO) is obtained from the fruit of 
the olive tree (Olea europea L.) solely by mechanical 
or other physical means under conditions that do 
not alter its natural composition.
Traditionally the beneficial effects of  EVOO 
have been ascribed to oleic acid by influencing 
arachidonic acid metabolism (Bermúdez et al., 
2011; Carrillo et al., 2012). However, a wide range 
of  evidence indicates that many of  the beneficial 
effects of  EVOO intake are due to its minor highly 
bioactive components (about 1–2% of  oil weight) 
(Alarcón de la Lastra et al., 2001). Among them, 
phenolic compounds such as hydroxytyrosol, tyro-
sol and oleuropein have shown anti-inflammatory 
and antioxidant effects (Omar, 2010). Current 
experimental studies support a beneficial role of 
the polyphenols from EVOO in several inflam-
matory diseases, including RA (Gong et al., 2009; 
Impellizzeri et al., 2011; Martinez-Dominguez 
et al., 2001). Although EVOO has demonstrated 
anti-inflammatory effects, little evidence has been 
reported regarding its possible immunomodula-
tory effects.
2. MATERIALS AND METHODS
2.1. Animals, diets and treatments
2.1.1. Collagen-induced arthritis (CIA)
Arthritis was induced in male DBA-1/J mice 
(Janvier, Le Genest St Isle, France) of  11 weeks 
of  age. All studies were performed in accordance 
with European Union regulations for the handling 
and use of  laboratory animals. The protocols were 
approved by the institutional Animal Care and 
Use Committee (University of  Valencia, Spain). 
Bovine collagen type II (CII) (2 mg/mL in dilute 
acetic acid; MD Biosciences, Zürich, Switzerland) 
was emulsified in equal volumes of  Freund’s com-
plete adjuvant (2 mg/mL Mycobacterium tubercu-
losis, strain H37Ra; Difco, Detroit, MI, USA). On 
day 0, DBA-1/J mice were immunized at the base 
of  the tail with 100 μg of  bovine CII. On day 21, 
the mice received an intra-peritoneal booster injec-
tion of  100 μg of  CII dissolved in a phosphate-
buffered saline. The mice were considered to have 
arthritis when significant changes in redness and/
or swelling were noted in the digits or in other 
parts of  the paws. Joint inflammation was scored 
visually in each paw, using a scale of  0–2 where 
0 = uninflamed, 1 = mild, 1.5 = marked and 2 = 
severe. Scoring was performed by two independent 
observers without any knowledge of  the experi-
mental groups.
2.1.2. EVOO versus SO diets
Three-week-old male DBA-1/J mice were ran-
domly placed into four experimental groups: 
(1) The Sham sunflower diet (SO-Sham) group 
received a diet elaborated with a marketable sun-
flower oil; (2) The CIA sunflower diet (SO-CIA) 
group received a diet elaborated with a marketable 
sunflower oil; (3) Sham EVOO diet (EVOO-Sham) 
group were fed with a diet made with a marketable 
EVOO characterized by a high content in polyphe-
nolic compounds (600ppm) (Oleoestepa®, Seville, 
Spain) and (4) The CIA EVOO diet (EVOO-CIA) 
group were fed with a diet made with a market-
able EVOO characterized by a high content in 
polyphenolic compounds (600ppm) (Oleoestepa®, 
Seville, Spain). All diets were formulated on the 
basis of  the American Institute of  Nutrition (AIN) 
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standard reference diet with the modification of 
various sources of  carbohydrate, at 10% of  oil 
and were prepared by mixing the respective com-
pounds under yellow light and stored at −80 °C. 
Fresh diets were provided daily. The animals were 
fed with the corresponding diet for six weeks pre-
vious to the CIA induction and during the experi-
ment time.
2.1.3. PE treatment
On day 29 after first immunization, the animals 
were randomly placed into control and treatment 
groups. The study was performed on four groups 
of mice (n = 10): Sham group (Sham), CIA group 
(CIA) and two treatment groups: CIA mice with 
phenolic extract (PE) treatment (PE 100 and 200 
mg/kg, orally, once a day from days 29 to 41). PE 
was obtained according to the method described by 
Vazquez Roncero et al. (Vázquez-Roncero, 1976).
2.2. Assessment of inflammatory mediators and 
mechanism
On day 42 after immunization mice were anes-
thetized, blood samples were taken through an 
intra-cardiac puncture and the animals were killed 
by cervical dislocation. Their paws were amputated 
and processed for either histological analysis or 
homogenization and assessment of inflammatory 
mediators and mechanisms.
To perform histological analyses, knee joints 
were fixed in 4% formalin. After decalcification in 
10% EDTA, the specimens were processed for paraf-
fin embedding. Tissue sections (7 μm) were stained 
with haematoxylin and eosin.
IL-1β and TNF-α levels were measured in the 
hind paw homogenates using ELISA kits.
Changes in protein expression were determined 
in hind paw homogenates by the western blot anal-
ysis. The antibodies used were: rabbit polyclonal 
anti-IκB-α (1:1000; Cell Signalling Technology, 
USA), rabbit polyclonal p65 (1:200, Santa Cruz 
Biotechnology, Inc.), rabbit polyclonal anti p-JNK 
and rabbit polyclonal anti-JNK (1:1000; Santa Cruz 
Biotechnology, Inc.), mouse polyclonal anti-p-p38 
and rabbit polyclonal anti-p38 (1:1000; Santa Cruz 
Biotechnology, Inc.) and mouse polyclonal anti- 
p-STAT3 (1:200; Santa Cruz Biotechnology, Inc.).
2.3. Data analysis
All values in the figures and text are expressed as 
arithmetic means± S.E.M. Data were evaluated with 
Graph Pad Prism Version 5.04 software. Statistical 
significance was evaluated by two-way (time course) 
or one-way (rest of parameters) analysis of variance 
(ANOVA), followed by Bonferroni’s test. P values 
<.05 were considered statistically significant.
3. RESULTS AND DISCUSSION
Our results revealed that EVOO, as the lipid 
component in the diet, and its PE effectively exhib-
ited preventive and therapeutic effects, respectively, 
in the development of inflammatory arthritis and 
joint damage in CIA arthritic mice in compari-
son with those CIA mice fed with SO or the stan-
dard diet (Figure 1). This effect was correlated to 
an improved arthritis score, a minor inflammatory 
cell infiltration into articular tissues, reduced exu-
dation into the synovial space, synovial hyperplasia 
and cartilage erosion (Figure 2). Over-expression 
of pro-inflammatory cytokines, such as IL-1β and 
TNF-α may activate osteoclasts and macrophages 
and recruit leukocytes in inflamed joints. It is well-
known that IL-17 is able to induce the release of IL-8 
and IL-6, and plays a remarkable role in the addi-
tive/synergistic effects induced by TNF-α and IL-1β 
(Jeong et al., 2004). Our results indicate that animals 
fed an EVOO diet or treated with the PE showed 
a significant reduction in IL-1β and TNF-α pro-
inflammatory cytokines levels in paw homogenates 
(Figure 3). Abnormal signaling pathways play an 
important role in the inflammatory process and can 
lead to a deregulation of the inflammatory response 
which is crucial in RA pathogenesis. Nuclear factor 
κB (NF-κB) is a crucial transcriptional activator for 
the expression of multiple pro-inflammatory genes 
involved in the microenvironment of the arthritic 
joints, playing an important role in the development 
of RA. (Morel and Berenbaum, 2004; Okamoto 
et al., 2010). Our results suggested that dietary 
EVOO and PE treatment suppressed NF-κB acti-
vation in CIA-induced arthritic mice (Figure 4). 
Similarly, the mitogen-activated protein kinase 
(MAPK) family also plays critical roles in RA patho-
genesis (Han et al., 2001; Suzuki et al., 2000) regu-
lating cytokine production, and activating the janus 
kinase-signal transducer and activator of the tran-
scription (JAK-STAT) signaling pathway through 
STAT-3 phosphorylation (Aaronson and Horvath, 
2002). Our results demonstrated that a EVOO diet 
and PE treatment intake significantly reduced both 
MAPKs and STAT-3 activation (Figures 5 and 6).
Altogether, our results confirm, for the first time, 
that EVOO and its minor polyphenolic fraction 
intake dramatically attenuated the progression and 
severity of arthritis in CIA DBA/1 J mice through 
NF-κB, MAPKs and JAK-STAT signaling pathway 
inhibition, decreasing the inflammatory cascade 
induced by CIA.
4. CONCLUSIONS
Our results suggest that EVOO exerts preven-
tive effects in the development of experimental RA, 
with its multiple minor components playing a key 
role in these healthy benefits. Thus, EVOO may be 
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Figure 1. Time course of the arthritis macroscopic score and representative photographs of hind paws at the end of the 
experiment (day 42). (A) Dietary EVOO treatment: SO-Sham, non-arthritic mice fed with SO diet; EVOO-Sham, non-arthritic mice 
fed with EVOO diet; SO-CIA, control arthritic group fed with SO diet; EVOO-CIA, arthritic mice fed with EVOO diet. (B) PE 
treatment: Sham, non-arthritic mice; CIA, control arthritic group; PE 100, arthritic mice treated with PE (100 mg/kg/day p.o. from 
days 29 to 41 after immunization); PE 200, arthritic mice treated with PE (200mg/kg/day p.o. from days 29 to 41 after immunization. 
Data represent mean ± S.E.M. n=10. *p <0.05 and **p<0.01 vs. Sham; +p<0.05 and ++p<0.01 vs. CIA.
Figure 2. Histological analysis of the frontal sections of knee joints on day 42. Sections were stained with H&E. Original 
magnification x200. (A) Dietary EVOO treatment: SO-Sham, non-arthritic mice fed with SO diet; EVOO-Sham, non-arthritic mice 
fed with EVOO diet; SO-CIA, control arthritic group fed with SO diet; EVOO-CIA, arthritic mice fed with EVOO diet. (B) PE 
treatment: Sham, non-arthritic mice; CIA, control arthritic group; PE 200, arthritic mice treated with PE (200mg/kg/day p.o. from 
days 29 to 41 after immunization. The images are representative of at least six experiments performed on different days.
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Figure 3. Measurement of TNF-α and IL-1β levels in hind paw homogenates. These were determined by ELISA kits. (A) Dietary 
EVOO treatment: SO-Sham, non-arthritic mice fed with SO diet; EVOO-Sham, non-arthritic mice fed with EVOO diet; SO-CIA, 
control arthritic group fed with SO diet; EVOO-CIA, arthritic mice fed with EVOO diet. (B) PE treatment: Sham, non-arthritic mice; 
CIA, control arthritic group; PE 100, arthritic mice treated with PE (100 mg/kg/day p.o. from days 29 to 41 after immunization); PE 
200, arthritic mice treated with PE (200mg/kg/day p.o. from days 29 to 41 after immunization. Data represent mean ± S.E.M., n = 10. 
**p<0.01 and ***p<0.001 vs. Sham; +p<0.05, ++p<0.01 and +++p<0.001 vs. CIA.
Figure 4. Expression of IκB-α in cytoplasmic fraction and p65 NF-κB in nuclear fraction of homogenates from hind paws. (A) 
Dietary EVOO treatment: SO-Sham, non-arthritic mice fed with SO diet; EVOO-Sham, non-arthritic mice fed with EVOO diet; 
SO-CIA, control arthritic group fed with SO diet; EVOO-CIA, arthritic mice fed with EVOO diet. (B) PE treatment: Sham, non-
arthritic mice; CIA, control arthritic group; PE 100, arthritic mice treated with PE (100 mg/kg/day p.o. from days 29 to 41 after 
immunization); PE 200, arthritic mice treated with PE (200mg/kg/day p.o. from days 29 to 41 after immunization. The expression was 
quantified by densitometry and normalized with respect to β-actin. Data represent mean ± S.E.M., n = 4. *p<0.05, **p<0.01 and 
***p<0.001 vs. Sham; +p<0.05 and ++p<0.01 vs. CIA.
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Figure 5. Changes in p-STAT3 protein expression in hind paw homogenates. (A) Dietary EVOO treatment: SO-Sham, non-arthritic 
mice fed with SO diet; EVOO-Sham, non-arthritic mice fed with EVOO diet; SO-CIA, control arthritic group fed with SO diet; EVOO-
CIA, arthritic mice fed with EVOO diet. (B) PE treatment: Sham, non-arthritic mice; CIA, control arthritic group; PE 100, arthritic 
mice treated with PE (100 mg/kg/day p.o. from days 29 to 41 after immunization); PE 200, arthritic mice treated with PE (200mg/kg/day 
p.o. from days 29 to 41 after immunization. The expression of p-STAT3 was quantified by densitometry and normalized with respect to 
β-actin. Data represent mean ± S.E.M., n = 4. ***p<0.001 vs. Sham; ++p<0.01 and +++p<0.001 vs. CIA.
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Figure 6. Effect of dietary EVOO on JNK and p38 MAPKs phosphorylation in hind paw homogenates. (A) Dietary EVOO 
treatment: SO-Sham, non-arthritic mice fed with SO diet; EVOO-Sham, non-arthritic mice fed with EVOO diet; SO-CIA, control 
arthritic group fed with SO diet; EVOO-CIA, arthritic mice fed with EVOO diet. (B) PE treatment: Sham, non-arthritic mice; CIA, 
control arthritic group; PE 100, arthritic mice treated with PE (100 mg/kg/day p.o. from days 29 to 41 after immunization); PE 200, 
arthritic mice treated with PE (200 mg/kg/day p.o. from days 29 to 41 after immunization. The expression of phosphorylated proteins 
was expressed related to the expression of the corresponding total protein. Data represent mean ± S.E.M., n = 4. **p<0.01 and 
***p<0.001 vs. Sham; +p<0.05, ++p <0.01 vs. CIA.
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considered as supportive nutritional therapy for RA 
patients and its polyphenolic fraction may provide 
an attractive nutraceutical complement in the man-
agement of RA, mainly when the effects of inex-
pensive, side effect-free therapies based on dietary 
EVOO might suppose an improvement in public 
health and the prevention of chronic pathologies 
with high prevalence in the population.
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